Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Xu, Jian Wei ^a   Wang, Tian Xiao ^b   You, Lei ^a   Zheng, Lian Fang ^a   Shu, Hong ^a   Zhang, Tai Ping ^a   Zhao, Yu Pei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GEMCITABINE; MICRORNA; MICRORNA 497; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; MIRN497 MICRORNA, HUMAN; RNA; TUMOR MARKER; TUMOR PROTEIN;

3' UNTRANSLATED REGION; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UPREGULATION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL PROLIFERATION; DEOXYCYTIDINE; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICRORNAS; NEOPLASM PROTEINS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RNA, NEOPLASM; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84899736575     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092847     Document Type: Article

References (28)

1. Trajkovic-Arsic M, Kalideris E, Siveke JT (2013) The role of insulin and IGF system in pancreatic cancer. J Mol Endocrinol 50: R67-74.
2. Costello E, Greenhalf W, Neoptolemos JP (2012) New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9: 435-444.
3. Winter JM, Yeo CJ, Brody JR (2013) Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol 107: 15-22.
4. Macgregor-Das AM, Iacobuzio-Donahue CA (2013) Molecular pathways in pancreatic carcinogenesis. J Surg Oncol 107: 8-14.
5. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
6. Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4: 143-159.
7. Li D, Zhao Y, Liu C, Chen X, Qi Y, et al. (2011) Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 17: 1722-1730.
8. Luo M, Shen D, Zhou X, Chen X, Wang W (2013) MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1receptor. LID - S0039-6060(12)00751-9 [pii]LID - 10.1016/j.surg.2012.12.004 [doi]. Surgery.
9. Guo ST, Jiang CC, Wang GP, Li YP, Wang CY, et al. (2013) MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 32: 1910-1920.
10. Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6: 1-12. (Pubitemid 46206663)
11. Hakam A, Fang Q, Karl R, Coppola D (2003) Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig Dis Sci 48: 1972-1978. (Pubitemid 37410086)
12. Valsecchi ME, McDonald M, Brody JR, Hyslop T, Freydin B, et al. (2012) Epidermal growth factor receptor and insulin like growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer 118: 3484-3493.
13. Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, et al. (1986) Characterization of a new primary human pancreatic tumor line. Cancer Invest 4: 15-23. (Pubitemid 16103427)
14. Kleeff J, Wildi S, Friess H, Korc M (1999) Ligand induced upregulation of the type II transforming growth factor (TGF-beta) receptor enhances TGF-beta responsiveness in COLO-357 cells. Pancreas 18: 364-370. (Pubitemid 29203309)
15. Chen WH, Horoszewicz JS, Leong SS, Shimano T, Penetrante R, et al. (1982) Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro 18: 24-34. (Pubitemid 12116070)
16. Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA, et al. (2013) Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in nonsmall cell lung cancer. LID - S0006-291X(13)00780-8 [pii]LID - 10.1016/j.bbrc.2013.05. 010 [doi]. Biochem Biophys Res Commun.
17. Shen L, Li J, Xu L, Ma J, Li H, et al. (2012) miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Exp Ther Med 3: 475-480.
18. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12: 159-169.
19. Tian X, Hao K, Qin C, Xie K, Xie X, et al. (2013) Insulin-Like Growth Factor 1 Receptor Promotes the Growth and Chemoresistance of Pancreatic Cancer. Dig Dis Sci 58: 2705-12.
20. Zhang XH, Chen SY, Tang L, Shen YZ, Luo L, et al. (2013) Myricetin Induces Apoptosis in Hepg2 Cells through Akt/P70s6k/Bad Signaling and Mitochondrial Apoptotic Pathway. Anticancer Agents Med Chem 13: 1575-81.
21. Faissner A, Heck N, Dobbertin A, Garwood J (2006) DSD-1-Proteoglycan/ Phosphacan and receptor protein tyrosine phosphatase-beta isoforms during development and regeneration of neural tissues. Adv Exp Med Biol 557: 25-53. (Pubitemid 43812306)
22. Chen D, Niu M, Jiao X, Zhang K, Liang J, et al. (2012) Inhibition of AKT2 Enhances Sensitivity to Gemcitabine via Regulating PUMA and NF-kappaB Signaling Pathway in Human Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 13: 1186-1208.
23. Caramuta S, Lee L, Ozata DM, Akcakaya P, Xie H, et al. (2013) Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma. Endocr Relat Cancer 20: 551-564.
24. Zhu W, Zhu D, Lu S, Wang T, Wang J, et al. (2012) miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 29: 384-391.
25. Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, et al. (2013) The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLOS ONE 8: e60155.
26. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
27. Ozkan EE (2011) Plasma and tissue insulin-like growth factor-I receptor (IGFIR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol 344: 1-24.
28. O'Kusky J, Ye P (2012) Neurodevelopmental effects of insulin-like growth factor signaling. Front Neuroendocrinol 33: 230-251.